NNNN (Anbio Biotechnology) Retained Earnings: $23.58 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NNNN Anbio Biotechnology NNNN
24 GF Score
Price $10.75
! 2 Warning Signs
View Full Analysis

What is Anbio Biotechnology Retained Earnings?

Anbio Biotechnology NNNN -7.01% 24 Retained Earnings is $23.58 Mil as of Dec. 2025. GuruFocus rates NNNN with a GF Score™ of 24/100. The stock has 2 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Anbio Biotechnology's retained earnings for the quarter that ended in Dec. 2025 was $23.58 Mil.

Anbio Biotechnology's quarterly retained earnings increased from Dec. 2024 ($17.17 Mil) to Jun. 2025 ($20.97 Mil) and increased from Jun. 2025 ($20.97 Mil) to Dec. 2025 ($23.58 Mil).

Anbio Biotechnology's annual retained earnings increased from Dec. 2023 ($14.80 Mil) to Dec. 2024 ($17.17 Mil) and increased from Dec. 2024 ($17.17 Mil) to Dec. 2025 ($23.58 Mil).


Anbio Biotechnology  (NAS:NNNN) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Anbio Biotechnology Retained Earnings Historical Data

* Premium members only.

The historical data trend for Anbio Biotechnology's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anbio Biotechnology Retained Earnings Chart

Anbio Biotechnology Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
2.54 12.55 14.80 17.17 23.58

Anbio Biotechnology Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Retained Earnings Get a 7-Day Free Trial Premium Member Only 14.80 18.40 17.17 20.97 23.58
NNNN
24GF Score
Anbio Biotechnology NNNN
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anbio Biotechnology Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of $23.58 Mil mean?
Anbio Biotechnology (NNNN) has a Retained Earnings of $23.58 Mil as of Dec. 2025. Retained earnings is the amount of net income not issued to shareholders. View historical data on Anbio Biotechnology and its competitors.
Is Anbio Biotechnology's Retained Earnings too high?
Anbio Biotechnology's current Retained Earnings is $23.58 Mil. Overall, Anbio Biotechnology has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Anbio Biotechnology's Retained Earnings compare to ANGO and OSUR?
Anbio Biotechnology's Retained Earnings of $23.58 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Medical Devices & Instruments company?
A good Retained Earnings depends on the Medical Devices & Instruments industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Anbio Biotechnology and its competitors. Anbio Biotechnology's current Retained Earnings is $23.58 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anbio Biotechnology stock overvalued right now?
Anbio Biotechnology (NNNN) has a current Retained Earnings of $23.58 Mil. The current Retained Earnings is $23.58 Mil. Anbio Biotechnology's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Anbio Biotechnology (NNNN), the current Retained Earnings is $23.58 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anbio Biotechnology Business Description

Other Exchanges N3B:Germany
Address Friedrich-Ebert-Anlage 35-37, Frankfurt am Main, HE, DEU, 60327
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
24GF Score

Get the complete analysis for NNNN

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.75
Price